How Noxopharm spent a pandemic-plagued 2020 leading the fight against cancer
Amid the tragedy of 2020’s global COVID-19 pandemic, it’s easy to forget the horrors inflicted on hundreds of
News
Biotech
News
Antisense Therapeutics’ Phase II Trials Show Promise for New Muscular Dystrophy Drug
Duchenne’s Muscular Dystrophy (DMD) is a devastating generic muscular wasting disorder with a 100% fatality rate . At
Webcast
Antisense Therapeutics Investor Briefing – 18 November
Antisense Therapeutics (ASX: ANP) is an Australian biotechnology company, developing and commercializing antisense pharmaceuticals for large unmet markets
Webcast
The Insider – 18 November
This week we were joined by the CEOs of exciting ASX listed businesses, who gave valuable insight to
Webcast
Prescient Therapeutics Investor Briefing – 4 November
Prescient Therapeutics (ASX:PTX) are focused on developing novel, personalised therapies for a range of cancers through universal CAR-T
News
Prescient Therapeutics – Interview with Dr Allen Ebens
In the battle against blood cancer, chimeric antigen receptor T cell (CAR-T) therapy is proving to be a
Webcast
Meet The CEOs – 21 October
This week we were joined by the CEOs of exciting ASX listed businesses, who gave valuable insight to
News
Ava Risk Group uncovers new opportunities for its fibre optic tech
A main priority for many boards of large companies in recent years has been risk management, following a
News
Orthocell gives mobility back to quadriplegic patients
Orthocell's (ASX: OCC) regenerative device, CelGro, is helping give mobility back to quadriplegic patients.
Webcast
Orthocell Limited Investor Briefing – 23 September
Orthocell Limited (ASX: OCC) is a world-leading regenerative medicine company providing innovative products to restore mobility, function and